Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
Presence of a complex karyotype did not affect progression-free or overall survival.
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy.
Over half of patients with
TP53-mutated acute myeloid leukemia who received the combination therapy experienced a response.
In a review article, researchers discussed maintenance treatment strategies using chemotherapy, immunotherapy, targeted small molecules, and more.
Nilotinib was associated with high adherence to treatment and fairly high quality of life, and nearly all evaluated patients achieved a major molecular response.
Certain malignancies, younger age at diagnosis, and multiple affected relatives were all associated with increased familial relative risks.
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
Further studies needed to look at relevance outside of the transplant-eligible population.
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
As oncologists welcome new chronic lymphocytic leukemia treatments, one researcher creates a scoring system to make the case for transplants.
At 3 years, the rates of overall and leukemia-free survival were 45% and 41%, respectively.
Patients with ADAMTS13 activity below a cutoff of 481 ng/mL had more bone marrow transplant-related complications, according to researchers.
Patients who received ibrutinib and rituximab had a 3-year PFS rate of 89.4%, compared with 72.9% in patients receiving chemoimmunotherapy.
Oncologists are changing the way they treat, perhaps too quickly and with too little evidence — but the behavior may signal a bigger problem with how research is reported.
Median overall survival was 42 months in patients who received sorafenib and 13 months in patients who received chemotherapy alone.
Type of chemotherapy did not result in significant differences in disease-free or overall survival.
The Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan (Genentech and Biogen), for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangitis and microscopic polyangiitis. The approval was based on a comprehensive data package which included results from the REFLECTIONS B3281006 study in…
Researchers sought to develop a model that can be used to identify patients receiving targeted therapy for CLL who are at high risk for poor outcomes.
Inferior survival for patients with chronic lymphocytic leukemia who progress with lymphadenopathy
Many clinical and ethical factors influence whether preemptive transplant would be beneficial for patients genetically predisposed to acute myeloid leukemia.
An alternative measure of relapse risk is needed in patients for whom no polymerase chain reaction marker is available.
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
The majority of patients achieved complete remission with or without incomplete count recovery after receiving 12 cycles of combination therapy.
The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Rates of leukemia-free and overall survival were 20% and 30%, respectively, at 2 years and 12% and 14%, respectively, at 5 years.
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Researchers evaluated response rates to azacitidine and decitabine in patients with chronic myelomonocytic leukemia according to various sets of response criteria.
Results from ongoing trials suggest targeted therapy may improve survival outcomes in acute myeloid leukemia, but further research is needed.
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.
Researchers sought to expand upon what is known about smoking status and AML diagnosis and understand more about how smoking affects treatment outcomes.
A significantly greater proportion of patients in the flumatinib group had a complete molecular response at 12 months compared with in the imatinib group.
The e13a2 transcript was expressed more frequently in men and pediatric patients.
Patients receiving idelalisib experienced longer median overall survival compared with patients receiving placebo.
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Twitter is increasingly being used by oncologists as a tool to communicate advancements in in the treatment of cancer. What could go wrong?
Propensity score analysis showed that patients in the inotuzumab ozogamicin arm experienced significantly longer event-free and overall survival.
What is the role of the clinician in managing financial toxicity?
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
High risk for tumor lysis syndrome and creatinine clearance below 80 mL/min were associated with tumor lysis syndrome development.
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Patients enrolled in a phase 1 trial receiving ibrutinib demonstrated augmented ex vivo CAR T-cell expansion.
Your patients may have questions about leukemia. Help them better understand the condition by sharing this article with them.